Stock comparison
IDEXX Laboratories
Veracyte
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
IDXX
IDEXX Laboratories
Market cap
$44.06B
Sector
Healthcare
VCYT
Veracyte
Market cap
$3.61B
Sector
Healthcare
Overall winner
IDEXX Laboratories IDXX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | IDXX | VCYT | Winner |
|---|---|---|---|
| Warren Buffett | 75B | 50D | IDXX |
| Benjamin Graham | 80A | 61D | IDXX |
| Philip Fisher | 75B | 65C | IDXX |
| Peter Lynch | 71B | 72B | VCYT |
| Joel Greenblatt | 83C | 50D | IDXX |
| Charlie Munger | 87A | 51D | IDXX |
| Terry Smith | 84A | 56D | IDXX |
Side-by-side metrics
| Metric | IDXX | VCYT |
|---|---|---|
| Market cap | $44.06B | $3.61B |
| P/E (TTM) | 39.0x | 34.8x |
| EV/EBIT | 31.6x | 38.4x |
| ROIC (TTM) | 40.66% | 4.73% |
| Gross margin | 62.05% | 71.31% |
| Net margin | 24.63% | 16.25% |
| Revenue CAGR 5y | 7.56% | 23.89% |
| EPS CAGR 5y | 10.79% | - |
| Debt / Equity | 0.7x | 0.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
IDXX leads on
- Market cap$44.06Bvs $3.61B+92%
- ROIC (TTM)40.66%vs 4.73%+88%
- Net margin24.63%vs 16.25%+34%
- EV/EBIT31.6xvs 38.4x+18%
VCYT leads on
- Debt / Equity0.0xvs 0.7x+96%
- Revenue CAGR 5y23.89%vs 7.56%+68%
- Gross margin71.31%vs 62.05%+13%
- P/E (TTM)34.8xvs 39.0x+11%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.